Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on February 13, 2026.
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Akums Drugs and Pharmaceuticals' board approved Q3 FY26 results on February 13, 2026. Consolidated revenue from operations grew to ₹11,595.87 million, up about 14.8% YoY from ₹10,104.11 million, while consolidated PAT for the quarter was ₹676.74 million vs ₹663.12 million. On a standalone basis, Q3 revenue rose modestly to ₹3,686.06 million (₹3,373.07 million YoY), but standalone PAT fell sharply to ₹281.14 million from ₹411.68 million, hit by an exceptional charge of ₹38.08 million related to the new Labour Codes. For nine months FY26, consolidated revenue stood at ₹32,001.49 million and consolidated PAT was ₹1,750.55 million (down from ₹1,941.71 million YoY). The auditor's limited review report is unqualified but includes an emphasis-of-matter paragraph on the ongoing Income Tax search and seizure matter from January 2025, whose financial impact remains unascertainable. The CDMO segment continues to dominate, contributing roughly 79% of consolidated external revenue in Q3.
Mixed picture for shareholders – top-line growth on a consolidated basis is healthy, especially in CDMO, but standalone profitability has been compressed by the Labour Codes exceptional item and the still-unresolved Income Tax investigation remains an overhang. The unqualified review with an emphasis-of-matter suggests no immediate accounting concern, but investors should watch for further developments on the tax proceedings and any margin pressure in the API and Trade Generics segments, which reported losses.